PROUD OF YOU @cancerassassin1.bsky.social

4/
Implications:
🔹Demonstrates feasibility of gene-editing intracellular checkpoints to overcome T cell exhaustion in solid tumors
🔹May be particularly promising cold tumor phenotypes resistant to PD-1 blockade
🔹First step toward "designer TILs" for refractory cancers

Clinical outcomes:
🔹1 pt with MSI-stable, PD-1 refractory CRC achieved CR lasting >21 months.
🔸3 pts had SD with tumor shrinkage (per RECIST v1.1).
🔹Persistence of edited T cell clones detected by bulk and scRNAseq post-infusion.

BASICS:
🔸13 pts treated after lymphodepleting chemo (cyclophosphamide/fludarabine).
🔹Infused with autologous CRISPR-edited TILs (median CISH KO 94%).
🔸No CRS, neurotoxicity, GVHD, or serious gene editing-related AEs observed.